Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats

Critical Care Medicine

Volumn 37, Issue 4, 2009, Pages 1348-1354

  Li, Yan ^a   Cui, Xizhong ^a   Su, Junwu ^a   Haley, Michael ^a,b   MacArthur, Heather ^b   Sherer, Kevin ^a   Moayeri, Mahtab ^c   Leppla, Stephen H ^d   Fitz, Yvonne ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Bacillus anthracis lethal toxin; Rodent; Sepsis; Treatment; Vasopressor

Indexed keywords

ADRENALIN; ANTHRAX TOXIN; INTERLEUKIN 1BETA; LACTIC ACID; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NORADRENALIN; PLACEBO; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ADRENALIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; HEMODYNAMICS; LETHALITY; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SHOCK; SURVIVAL;

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BLOOD PRESSURE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SHOCK, SEPTIC; SURVIVAL RATE; VASOCONSTRICTOR AGENTS;

EID: 67650474225     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819cee38     Document Type: Article

References (46)

1. Mock M, Fouet A: Anthrax. Annu Rev Microbiol 2001; 55:647-671
2. Leppla SH: Anthrax toxin. In: Bacterial Proteins. Aktories K, Just I (Eds). New York, NY, Springer, 2000, pp 445-472
3. Ezzell JW, Ivins BE, Leppla SH: Immuno-electrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun 1984; 45:761-767
4. Molnar DM, Altenbern RA: Alterations in the biological activity of protective antigen of Bacillus anthracis toxin. Proc Soc Exp Biol Med 1963; 114:294-297
5. Pezard C, Berche P, Mock M: Contribution of individual toxin components to virulence of. Bacillus anthracis. Infect Immun 1991; 59: 3472-3477
6. Cui X, Li Y, Moayeri M, et al: Late treatment with a protective antigen derived monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis 2005; 191:422-434
7. Mohamed N, Clagett M, Li J, et al: A high-affinity monoclonal antibody to the anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 2005; 73: 795-802
8. Subramanian GM, Cronin PW, Poley G, et al: A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005; 41:12-20
9. Duesbery NS, Webb CP, Leppla SH, et al: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280:734-737
10. Vitale G, Pellizzari R, Recchi C, et al: Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured mac-rophages. J Appl Microbiol 1999; 87:288
11. Ho DT, Bardwell AJ, Abdollahi M, et al: A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J Biol Chem 2003; 278:32662-32672
12. Bardwell AJ, Abdollahi M, Bardwell L: Anthrax lethal factor-cleavage products of MAPK kinases exhibit reduced binding to their cognate MAPKs. Biochem J 2004; 378: 569-577
13. Cui X, Moayeri M, Li Y, et al: Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol 2004; 286:R699-R709
14. Kirby JE: Anthrax toxin induces human endothelial cell apoptosis. Infect Immun 2004; 72:430-439
15. Warfel JM, Steele AD, D'Agnillo F: Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 2005; 166:1871-1881
16. Gozes Y, Moayeri M, Wiggins JF, et al: Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect Immun 2006; 74:1266-1277
17. Sherer K, Li Y, Cui X, et al: Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: Implications for therapy. Am J Respir Crit Care Med 2007; 175: 211-221
18. Borio L, Frank D, Mani V, et al: Death due to bioterrorism-related inhalational anthrax: Report of 2 patients. JAMA 2001; 286: 2554-2559
19. Sherer K, Li Y, Cui X, et al: Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model. Crit Care Med 2007; 35:1560-1567
20. Cui X, Li Y, Li X, et al: Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 2007; 195:572-580
21. Park S, Leppla SH: Optimized production and purification of Bacillus anthracis lethal factor. Protein Expr Purif 2000; 18:293-302
22. Ramirez DM, Leppla SH, Schneerson R, et al: Production, recovery and immunogenicity of the protective antigen from a recombinant strain of. Bacillus anthracis. J Ind Microbiol Biotechnol 2002; 28:232-238
23. Macarthur H, Westfall TC, Riley DP, et al: Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc Natl Acad Sci USA 2000; 97:9753-9758
24. Quezado Z, Parent C, Karzai W, et al: Acute G-CSF therapy is not protective during lethal E. coli sepsis. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1177-R1185
25. Cobb JP, Danner RL: Nitric oxide and septic shock. JAMA 1996; 275:1192-1196
26. Dinarello CA: Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112:321S-329S
27. Zhu X, Bagchi A, Zhao H, et al: Toll-like receptor 2 activation by bacterial peptidogly-can-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med 2007; 35:886-892
28. Price S, Anning PB, Mitchell JA, et al: Myocardial dysfunction in sepsis: Mechanisms and therapeutic implications. Eur Heart J 1999; 20:715-724
29. Takakura K, Xiaohong W, Takeuchi K, et al: Deactivation of norepinephrine by peroxynitrite as a new pathogenesis in the hypotension of septic shock. Anesthesiology 2003; 98:928-934
30. Macarthur H, Couri DM, Wilken GH, et al: Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an Escherichia coli model of septic shock: Correlation with preserved circulating catecholamines. Crit Care Med 2003; 31:237-245
31. Morimatsu H, Singh K, Uchino S, et al: Early and exclusive use of norepinephrine in septic shock. Resuscitation 2004; 62:249-254
32. Hernandez G, Bruhn A, Romero C, et al: Management of septic shock with a norepi-nephrine-based haemodynamic algorithm. Resuscitation 2005; 66:63-69
33. Kalinichenko VV, Mokyr MB, Graf LH, et al: Norepinephrine-mediated inhibition of anti-tumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression. J Immunol 1999; 163:2492-2499
34. Turk BE: Manipulation of host signaling pathways by anthrax toxins. Biochem J 2007; 402:405-417
35. During RL, Gibson BG, Li W, et al: Anthrax lethal toxin paralyzes actin-based motility by blocking Hsp27 phosphorylation. EMBO J 2007; 26:2240-2250
36. Park JM, Greten FR, Li ZW, et al: Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 2002; 297:2048-2051
37. Comer JE, Galindo CL, Chopra AK, et al: GeneChip analyses of global transcriptional responses of murine macrophages to the lethal toxin of Bacillus anthracis. Infect Immun 2005; 73:1879-1885
38. Sapra R, Gaucher SP, Lachmann JS, et al: Proteomic analyses of murine macrophages treated with Bacillus anthracis lethal toxin. Microb Pathog 2006; 41:157-167
39. Alileche A, Squires RC, Muehlbauer SM, et al: Mitochondrial impairment is a critical event in anthrax lethal toxin-induced cytolysis of murine macrophages. Cell Cycle 2006; 5:100-106
40. Watson LE, Kuo SR, Katki K, et al: Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS ONE 2007; 2:e466
41. Beall FA, Taylor MJ, Thorne CB: Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol 1962; 83:1274-1280
42. Bellomo R: Noradrenaline: Friend or foe? Heart Lung Circ 2003; 12:S42-S48
43. Bennett T, Mahajan RP, March JE, et al: Regional and temporal changes in cardiovascular responses to norepinephrine and vasopressin during continuous infusion of lipopolysaccharide in conscious rats. Br J Anaesth 2004; 93:400-407
44. Firoved AM, Miller GF, Moayeri M, et al: Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol 2005; 167:1309-1320
45. Van Amersfoort ES, Van Berkel TJ, Kuiper J: Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003; 16:379-414
46. Schutte F, Burgdorf C, Richardt G, et al: Adenosine A1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase. Can J Physiol Pharmacol 2006; 84:573-577